Edgewise CFO granted 48,750 options at $43.56

Edgewise Therapeutics, Inc. reported that Chief Financial Officer Michael Nofi received a grant of 48,750 stock options on August 12, 2026.

Rhea-AI Filing Summary

Edgewise Therapeutics, Inc. reported that Chief Financial Officer Michael Nofi received a grant of 48,750 stock options on August 12, 2026. These options have an exercise price of $43.56 per share, reflecting the fair market value on the grant date, and expire on August 12, 2036. The amendment clarifies that an earlier filing incorrectly showed a $0.00 exercise price due to a clerical error. According to the vesting terms, 1/48 of the options vest each month beginning on September 12, 2026, contingent on his continued service.

Insider Trade Summary

Grant/Award: 48,750 shares

Grant/Award 1 txn

Insider Nofi Michael

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	48,750	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 48,750 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

Options Granted: 48,750 options Exercise Price: $43.56 per share Shares Underlying Options: 48,750 shares +4 more

7 metrics

Options Granted 48,750 options Stock Option (Right to Buy) grant to CFO Michael Nofi on August 12, 2026

Exercise Price $43.56 per share Corrected exercise price reflecting fair market value on grant date

Shares Underlying Options 48,750 shares Common stock underlying the reported stock option award

Options After Transaction 48,750 options Total derivative securities held from this grant following the reported acquisition

Vesting Rate 1/48 per month Monthly vesting of the option beginning September 12, 2026

Vesting Start Date September 12, 2026 First vesting date for the monthly installments of the option

Expiration Date August 12, 2036 Date after which the granted options are no longer exercisable

Key Terms

Stock Option (Right to Buy), exercise price, vesting, expiration date, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title is listed as Stock Option (Right to Buy)"

exercise price financial

"The correct exercise price is $43.56, which reflects the fair market value"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/48th of the shares subject to the option vest each month"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

expiration date financial

"expiration_date is reported as 2036-08-12 for the option grant"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

fair market value financial

"which reflects the fair market value of the underlying security on the date"

The price a willing buyer and a willing seller would agree on for an asset or security when neither is under pressure and both have access to the same information. Think of it as the market’s neutral estimate of what something is worth, like the price two neighbors would settle on for a car after comparing similar listings. Investors care because fair market value guides buying and selling decisions, tax reporting, portfolio valuation, and how accurately company assets are reflected in financial statements.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EWTX report for CFO Michael Nofi in this Form 4/A?

The filing reports a grant of 48,750 stock options to CFO Michael Nofi on August 12, 2026. These options are a compensation award with a defined vesting schedule and a fixed exercise price.

What is the corrected exercise price of Michael Nofi’s options in EWTX?

The corrected exercise price is $43.56 per share, matching the fair market value on the grant date. The amendment was filed because the original report mistakenly showed a $0.00 exercise price.

How many Edgewise Therapeutics (EWTX) options were granted to the CFO?

Michael Nofi was granted 48,750 stock options for Edgewise Therapeutics common stock. Following this grant, his reported derivative holdings from this award total 48,750 options, all subject to future vesting conditions.

What is the vesting schedule for Michael Nofi’s EWTX stock options?

The options vest in monthly installments of 1/48 of the total grant starting September 12, 2026. Vesting on each date is conditioned on Mr. Nofi continuing as a service provider to the company.

When do Michael Nofi’s EWTX stock options expire?

The stock options granted to Michael Nofi have an expiration date of August 12, 2036. After this date, any unexercised options from this grant will no longer be exercisable.

Did Edgewise Therapeutics indicate a Rule 10b5-1 trading plan for this EWTX option grant?

No. The filing’s Rule 10b5-1 indicator is unchecked, and there is no footnote stating that the option grant occurred under a Rule 10b5-1 trading plan or similar arrangement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/17/2026 - 06:42 PM Accepted by SEC EDGAR 08/17/2026 - 06:41 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nofi Michael

(Last) (First) (Middle)

1715 38TH STREET

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/14/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$43.56	08/12/2026		A		48,750		(1)	08/12/2036	Common Stock	48,750	$0.00	48,750	D

Explanation of Responses:

1. 1/48th of the shares subject to the option vest each month beginning on September 12, 2026, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

This amendment corrects the exercise price of the reported option grant, which was reported as $0.00 due to a clerical/administrative error. The correct exercise price is $43.56, which reflects the fair market value of the underlying security on the date of grant.

	/s/ John R. Moore, Attorney-in-Fact for Michael Nofi	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)